Clements P J
Curr Opin Rheumatol. 1995 Nov;7(6):517-21.
Now that guidelines for conducting trials of disease-modifying treatments in systemic sclerosis (SSc) have been published and guidelines for evaluating SSc organ-specific treatments are in preparation, our attention should focus on how to measure disease activity and severity in SSc. Several proposals for measuring disease severity have been forwarded and are discussed. In this editorial, what we know of SSc natural history and pathophysiology is reviewed, and several candidate variables that may reflect disease activity are proposed for evaluation in longitudinal studies and/or drug trials.
鉴于系统性硬化症（SSc）疾病修饰治疗试验的指南已发布，且SSc器官特异性治疗评估指南正在制定中，我们应将注意力集中在如何测量SSc的疾病活动度和严重程度上。已经提出并讨论了几种测量疾病严重程度的建议。在这篇社论中，我们回顾了已知的SSc自然史和病理生理学，并提出了几个可能反映疾病活动的候选变量，以供在纵向研究和/或药物试验中进行评估。
